Pharmos(PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Stums who wrote (1357)	10/8/1998 9:46:00 AM
From: Filbert	Read Replies (2) of 1491

Let me chime in with my two cents. To me the critical importance of the trials and the presentation has to do with the signing of a partner for HU-211. The Phase III studies will be very expensive and Pharmos cannot foot the bill. The successful Phase II will put them in a decent bargaining position, and take some of the risk out of the investment by the potential partner. I have some small concern about the time that will be required to sign a partner. It will be dead time for progress until this milestone is achieved. I never think that presented papers do much for a stock price. However, I forwarded the press release to a neurosurgeon friend of mine who won't be attending the conference to see what he thought. He called last night to ask me if the stock had increased that day. I repeated my belief that papers don't make any difference to Wall St. He said, "That's true, but there might be 200 neurosurgeons buying in tomorrow." So let's hope my friend is correct. If not, I had a pretty good laugh. Filbert

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next